Brief: Immuneering Reports Data In Two Preclinical Abstracts At The ASCO 2022
27/05/2022 24:40
May 26 (Reuters) - Immuneering Corp IMRX.O :
* IMMUNEERING REPORTS DATA IN TWO PRECLINICAL ABSTRACTS AT
THE ASCO 2022 ANNUAL MEETING HIGHLIGHTING PAN-KRAS/NRAS ACTIVITY
OF IMM-1-104
* IMMUNEERING CORP - IMM-1-104 IND EXPECTED IN Q3 2022;
ENROLLMENT
OF FIRST PATIENT IN PHASE 1 TESTING EXPECTED IN Q4 2022
Source text for Eikon: ID:nGNXc1BQjf
Further company coverage: IMRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Immuneering
See all newsImmuneering expects cash runway to fund operations into 2029
Immuneering posts smaller-than-expected Q1 net loss on lower R&D spend
U.S. STOCKS ON THE MOVE-GoPro, Prudential Financial, Whitestone REIT
U.S. STOCKS ON THE MOVE-US airlines, BlackRock, copper miners
U.S. STOCKS ON THE MOVE-Gap, Caterpillar, Solid Biosciences